(Nasdaq: AMIX) Has Analyst Targets Suggesting Triple-Digit Potential Upside (5 Potential Catalysts)

An innovative company in the medical device sector

*Sponsored (Nasdaq: AMIX) Has Analyst Targets Suggesting Triple-Digit Potential Upside (5 Potential Catalysts) This One Ran Approximately 77% Intraday Last Time It Topped My Watchlist! July 21st Greetings Readers, An innovative company in the medical device sector is drawing attention as it expands its breakthrough method for managing pain in cancer patients. Having recently received authorization to extend a clinical trial program, the organization is now including a range of visceral cancers in its research, moving beyond its original emphasis on pain associated with pancreatic cancer. Initial findings highlight notable reductions in pain for patients, along with lowered opioid consumption and improvements in daily living. The company's technology, which integrates sophisticated nerve detection with precise ablation techniques, positions it to address critical gaps in pain treatment. As clinical efforts broaden, the company's potential reach within the pain management field could grow significantly, making it a noteworthy Nasdaq profile to follow. It also doesn't hurt that a low float of fewer than 3Mn shares could create heightened volatility and a pair of analyst targets are pointing to triple-digit potential upside. Oh, yeah! I almost forgot to share... This isn't the first time I've brought this MedTech profile to your attention. Previously alerted towards the end of last month, this one ran approx. 77% intraday from an open of $1.37 to a high of $2.43 on June 27th. Listen. Take a second to consider this Nasdaq biotech profile for your watchlist: Autonomix Medical, Inc. (Nasdaq: AMIX) Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. And based on multiple potential breakout catalysts, (Nasdaq: AMIX) has taken over my watchlist's top spot. Check them out: No. 1 - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure. No. 2 - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!) No. 3 - First Patient Dosing Represents A Major Milestone As AMIX Looks To Double The Potential Addressable Market. No. 4 - A New U.S. Patent Helps AMIZ Strengthen Its Strategic Position In A Massive Market. No. 5 - Could Chart Support Levels Be Strengthening? But more on those in a second... Company Breakdown - All About Autonomix Medical, Inc. (Nasdaq: AMIX) Autonomix Medical, Inc. is pioneering a transformative approach to nerve-targeted treatments, leveraging proprietary transvascular, precision-guided technology to address unmet needs in neurological and pain management markets. The company’s mission centers on “Sense, Treat, and Verify,” a paradigm that enables real-time, high-resolution mapping and ablation of overactive nerves, particularly those implicated in severe pain syndromes such as pancreatic cancer-related pain. Technology and Intellectual Property Autonomix has developed a first-in-class platform with an extensive intellectual property portfolio, boasting over 120 patents issued and pending. Its proprietary technology features a miniaturized, application-specific integrated circuit (ASIC) microchip (1–2 mm in size), paired with a custom antenna array. This system is designed for ultra-high sensitivity, capable of detecting and differentiating neural signals less than 5 microvolts—far below the detection threshold of current cardiac sensing technologies, which typically sense signals above 100 microvolts. The close proximity of the sensory chip to the antenna allows for immediate, high-resolution signal capture directly at the source, enabling precise targeting and real-time feedback during procedures. Clinical Achievements and Pipeline Autonomix’s initial proof-of-concept (PoC 1) trial focused on the treatment of intractable pain associated with pancreatic cancer, a leading cause of morbidity and mortality with a high prevalence of severe, difficult-to-manage pain. The PoC 1 study involved 20 subjects across one clinical site, with the majority of patients treated via femoral access. Results demonstrated statistically significant pain reduction, with 100% of femoral-access patients responding to treatment. Notably, pain relief was observed as early as 24 hours post-procedure. At the 4–6 week follow-up, responding patients experienced a mean pain reduction of 4.67 points (59.2%) on the Visual Analog Scale (VAS), which is considered clinically meaningful. Furthermore, 100% of responders required zero opioid use at 7 days, and 73% remained opioid-free at 4–6 weeks, even as their disease progressed. No device or procedure-related serious adverse events were reported, underscoring the safety and tolerability of the approach. Market Opp. and Expansion The company estimates a combined market opp. exceeding $100Bn across a wide spectrum of neurological and pain-related diseases. Autonomix is preparing to launch PoC 2, an expansion study targeting additional visceral cancers (gallbladder, liver, bile duct) as well as earlier-stage pancreatic cancer. This expansion is expected to double the addressable market beyond pancreatic cancer pain alone. The platform’s versatility and minimally invasive nature position it for broad application in both diagnostic and therapeutic settings. Regulatory and Commercial Strategy Autonomix is targeting a De Novo submission to the FDA in 2026 for its pancreatic cancer-related pain indication, with potential clearance anticipated in 2027. This multi-pronged approach aims to drive recurring revenue and support long-term growth. Leadership and Vision Autonomix is led by a proven team with multiple successful exits in the medical technology sector. The company’s vision is to transform the standard of care for nerve-related disorders by providing physicians with unprecedented visibility and control over neural signaling, thereby improving patient outcomes and quality of life. This core summary encapsulates Autonomix’s breakthrough technology, clinical validation, market potential, regulatory strategy, and leadership, positioning the company as a leader in the next generation of nerve-targeted therapies. Grab Sources And More: AMIX Website. AMIX Presentation. ----- And based on a handful of potential catalysts I laid out earlier, (Nasdaq: AMIX) has quickly risen to the top spot on my watchlist. Take a look: No. 1 AMIX Potential Catalyst - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure. According to info from the Yahoo Finance website, AMIX has a very low float. The website reports this profile to have roughly 2.4Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. ----- No. 2 AMIX Potential Catalyst - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!) Two separate analysts are pointing to AMIX as potentially undervalued based on current chart positioning. Jeffrey S. Cohen of Ladenburg Thalmann Co. Inc. has set an $18 price target for AMIX.  Compared to Friday’s closing price, this forecast implies a potential upside exceeding 900%. Anthony Vendettii from Maxim Group has also issued a target for AMIX, setting it at $5.00.  From its Friday close, this price target suggests a potential upside of more than 175% for AMIX. ----- No. 3 AMIX Potential Catalyst - First Patient Dosing Represents A Major Milestone As AMIX Looks To Double The Potential Addressable Market. Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. “We’re executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said Brad Hauser, CEO of Autonomix. “The start of patient treatment in our PoC 2 study represents a major milestone that reinforces our momentum and marks a critical step toward unlocking substantial clinical and commercial potential. We believe this expansion strengthens our value proposition and positions us to deliver meaningful impact for patients while creating long-term value for shareholders. We look forward to sharing further updates as clinical data become available.” ... Read the full article here. ----- No. 4 AMIX Potential Catalyst - A New U.S. Patent Helps AMIZ Strengthen Its Strategic Position In A Massive Market. Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-Bn-dollar market opp. and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, “Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification.” The newly issued ‘899 patent relates to but is not limited to advanced systems and methods for locating, monitoring and mapping electrophysiological signals before, during and following a neuromodulation or denervation procedures. Furthermore, the patent explicitly contemplates tools to access small vessels and navigation to the target area to treat cancerous tumors and the pain associated with cancerous tumors. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders. “This granted patent represents a significant step forward in our mission to improve patient outcomes by delivering more effective, less invasive treatments for conditions involving the nervous system, including chronic pain, autonomic dysfunction associated with hypertension and a range of other nerve-related disorders. We are pleased to strengthen our IP portfolio and further enhance our intellectual property position in the rapidly growing nerve-focused therapeutics space, enabling us to protect our innovations and deliver improved solutions for both clinicians and patients,” commented Brad Hauser, CEO of Autonomix. ... Read the full article here. ----- No. 5 AMIX Potential Catalyst - Could Chart Support Levels Be Strengthening? At close on Friday, AMIX found itself in an interesting chart position. Finishing above 4 key technical levels on Friday, chart support could be strengthening for AMIX. These 4 levels could possibly be gaining strength: 20-Day Simple Moving Average (SMA) 50-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA Watch AMIX's chart closely because its 200-Day SMA could act as strong resistance, but it's still well above the $4.00 mark. ----- (Nasdaq: AMIX) Recap - These 5 Potential Catalysts Could Earn This Biotech Profile Serious Attention No. 1 - Volatility Potential Could Be Heightened Because Of AMIX's Low Float Structure. No. 2 - Two Analyst Targets Suggest Significant Upside Potential (More Than Triple-Digit!) No. 3 - First Patient Dosing Represents A Major Milestone As AMIX Looks To Double The Potential Addressable Market. No. 4 - A New U.S. Patent Helps AMIZ Strengthen Its Strategic Position In A Massive Market. No. 5 - Could Chart Support Levels Be Strengthening? ----- Coverage is again kicked off on Autonomix Medical, Inc. (Nasdaq: AMIX). When updates show up, I'll have them out to you quickly. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/21/2025 and ending on 07/21/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid fifty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/amix-eueyp/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice